---
title: "A Biological-Systems-Based Analyses Using Proteomic and Metabolic Network Inference Reveals Mechanistic Insights into Hepatic Lipid Accumulation: An IMI-DIRECT Study"
description: |
  * **Objective**: This multi-omics study used **Bayesian network analysis** and **Mendelian Randomization (MR)** on the IMI-DIRECT cohort to determine the causal network linking glucose/insulin dynamics, fat distribution (MRI), and plasma proteins to **MASLD (liver fat accumulation)**.
  * **Key Causal Driver**: **High Basal Insulin Secretion Rate (BasalISR)** was identified as the **primary causal driver** of liver fat accumulation in both the non-diabetes and Type 2 Diabetes cohorts, suggesting it is a modifiable therapeutic target.
  * **Mechanistic Insights**: The study revealed a self-reinforcing **bidirectional association** between **Visceral Adipose Tissue (VAT)** and liver fat. It also identified **sex-specific proteomic drivers** of liver fat, with **GUSB** being more predictive in females and **LEP** (Leptin) in males.
date: last-modified
categories: [bayesian network, causal inference, masld, mendelian randomization, metabolic disease, metabolomics, multi-omics, proteomics]
---

**PubMed:** [40502600](https://pubmed.ncbi.nlm.nih.gov/40502600/)
**DOI:** [10.1101/2025.06.02.25328773](https://doi.org/10.1101/2025.06.02.25328773)
**Overview generated by:** Gemini 2.5 Flash, 28/11/2025

## Study Goal and Context

Metabolic Dysfunction-Associated Steatotic Liver Disease (**MASLD**), formerly known as NAFLD, affects about a third of the global adult population, with prevalence rising to about 67% in people with **Type 2 Diabetes (T2D)**. The underlying metabolic and proteomic features driving the association between MASLD and T2D are poorly understood.

This study aimed to delineate the organ-specific and systemic drivers of MASLD by applying **integrative causal inference** across clinical, imaging, proteomic, and metabolic domains using data from the IMI-DIRECT prospective cohort study.

## Methods: Multi-Omics Causal Network Inference

The study analyzed data from the **IMI-DIRECT cohort** consisting of 331 adults with new-onset T2D and 964 adults without diabetes. Participants were comprehensively phenotyped, including:

* **Metabolic Measures:** Glucose and insulin dynamics from frequently-sampled metabolic challenge tests, including the **Basal Insulin Secretion Rate (BasalISR)** and insulin clearance (Clinsb).
* **Imaging Measures:** **MRI-derived fat content** in the liver and abdomen (Visceral Adipose Tissue - VAT).
* **Proteomics:** Plasma proteins were quantified using Olink Proximity Extension Assays (**446 proteins** initially analyzed).

The core analytical approach involved:

1.  **Bayesian Network Analysis:** Used to quantify potential **causal pathways** and interactions, generating **Directed Acyclic Graphs (DAGs)** to suggest cause-and-effect relationships between clinical and protein features.
2.  **Mendelian Randomization (MR):** Employed as a complementary technique for associations where the Bayesian network could not determine the causal direction with high probability (suggesting bidirectional links).

## Key Findings: Basal Insulin as the Causal Driver

### 1. Basal Insulin Hypersecretion Drives Liver Fat Accumulation
**High basal insulin secretion rate (BasalISR)** was identified as the **primary causal driver** of liver fat accumulation in both the non-diabetes and T2D cohorts.

* In the **non-diabetes network**, BasalISR was the parental node for both liver fat and Visceral Adipose Tissue (VAT), suggesting it drives fat accumulation in both ectopic (liver) and visceral areas.
* The effect of BasalISR on the liver is partially mediated through **VAT accumulation**.

### 2. Bidirectional and Consequence Pathways
* **VAT-Liver Fat Loop:** **Excess visceral adipose tissue (VAT)** was found to be **bidirectionally associated** with liver fat, indicating a self-reinforcing metabolic loop.
* **Insulin Clearance:** **Basal insulin clearance (Clinsb)** was identified as a **consequence** (downstream effect) of liver fat accumulation. This worsening of Clinsb was more pronounced *before* the onset of T2D.

### 3. Proteomic Drivers and Sex-Specific Differences
Of the 446 analyzed proteins, **34 were identified as key components** of the metabolic networks (27 in the non-diabetes network, 18 in the T2D network, and 11 common).

* **Directly Associated Proteins:** Key proteins directly associated with liver fat included **GUSB, ALDH1A1, LPL, IGFBP1/2, CTSD, HMOX1, FGF21, AGRP, and ACE2**.
* **Insulin-IGFBP Axis:** The network showed that basal hyperinsulinemia has a **direct inverse effect** on **IGFBP-1** (Insulin-like Growth Factor Binding Protein-1), a suppressive feedback loop consistent with IGFBP-1 being produced by the liver.
* **Sex-Stratified Drivers:** **GUSB** was the most predictive of liver fat in **females**, while **LEP** (Leptin) was most predictive in **males**, highlighting a sex-specific proteomic architecture of hepatic steatosis.

## Conclusions and Recommendations

The study concludes that **basal insulin hypersecretion** is a **modifiable, causal driver** of MASLD, especially prior to glycemic decompensation.

The findings demonstrate a complex, multifactorial, sex- and disease-stage-specific **proteo-metabolic architecture** of hepatic steatosis. Proteins such as GUSB, ALDH1A1, LPL, and IGFBPs warrant further investigation as potential **biomarkers or therapeutic targets** for MASLD prevention and treatment.